Edition:
United States

Profile: CEL-SCI Corp (CVM)

CVM on American Stock Exchange

0.27USD
27 Sep 2016
Change (% chg)

$-0.16 (-37.38%)
Prev Close
$0.44
Open
$0.30
Day's High
$0.34
Day's Low
$0.24
Volume
8,796,188
Avg. Vol
468,412
52-wk High
$0.75
52-wk Low
$0.24

CEL-SCI Corporation, incorporated on March 22, 1983, is a biotechnology company. The Company is engaged in the research and development of drugs and vaccines. The Company researches and develops immunotherapy products for the treatment of cancer and infectious diseases. The Company's product pipeline consists of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy against cancer and Human Papilloma Virus (HPV), and Ligand Epitope Antigen Presentation System (LEAPS) technology, with two investigational therapies, LEAPS-H1N1-DC pandemic flu treatment for hospitalized patients, and CEL-2000, a rheumatoid arthritis treatment vaccine.

Multikine

The Company's lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in the Phase III clinical trial against head and neck cancer. The Company has received Orphan Drug Status from the United States Food and Drug Administration for Multikine.

LEAPS

The Company's patented T-cell Modulation Process, referred to as LEAPS uses heteroconjugates to direct the body to choose a specific immune response. LEAPS is the Company's pre-clinical technology. LEAPS is designed to stimulate the human immune system to treat bacterial, viral and parasitic infections, as well as autoimmune, allergies, transplantation rejection and cancer. Using the LEAPS technology, the Company has created a peptide treatment for H1N1 (swine flu) hospitalized patients.

Company Address

CEL-SCI Corp

8229 Boone Blvd Ste 802
VIENNA   VA   22182-2634
P: +1703.5069460
F: +1703.5069471

Company Web Links